EUVIMEDEUVIMED entdecken
Crossref

Histopathological Study of Tumours and Tumour - Like Lesions of Skin

Nanditha H. S, Uma K, Akhila J, Shilpa S Biradar

International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)

DOI: 10.25258/ijcpr.18.7.232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Nanditha H. S und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumours and tumour- like lesions of skin constitute a wide spectrum, affecting all ages and both sexes. Skin adnexal tumours(SATs) present a diverse group, depending on their pattern of differentiation. Most SATs are benign. Although malignant skin tumours are rare, they tend to be aggressive, with a poor clinical outcome. In our study, epidermoid cyst was the commonest tumour- like lesion. The incidence of benign (68.75%) and malignant (31.25%) tumours reported in our study. Syringoma and pilomatricoma were the common benign neoplasms, with two cases each. Three cases of melanoma were reported, making them the commonest malignant tumours of skin.

Zitieren

APA

S, N. H., K, U., J, A., & Biradar, S. S. (2026). Histopathological Study of Tumours and Tumour - Like Lesions of Skin. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.232

Vancouver

S NH, K U, J A, Biradar SS. Histopathological Study of Tumours and Tumour - Like Lesions of Skin. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.232

BibTeX
@article{S2026,
  author = {S, Nanditha H. and K, Uma and J, Akhila and Biradar, Shilpa S},
  title = {Histopathological Study of Tumours and Tumour - Like Lesions of Skin},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {07},
  doi = {10.25258/ijcpr.18.7.232}
}
Kostenlos starten →